Both in Pharmaceuticals
Arcus Biosciences vs Palvella Therapeutics
Over the past year RCUS returned −2.6% and PVLA returned +116.2%; their daily moves had a correlation of 0.32.
RCUS −2.6% PVLA +116.2%Growth of $1, one year, split-adjusted
| Metric | RCUS | PVLA |
|---|---|---|
| Price | $19.31 | $162.28 |
| Market cap | $2.46B | $2.34B |
| Today | +2.12% | +6.11% |
| 1 month | −20.5% | +26.8% |
| 6 months | −25.7% | +24.7% |
| Year to date | −19.0% | +55.0% |
| 1 year | −5.1% | +111.2% |
| Revenue growth (YoY) | −74.4% | — |
| Gross margin | 100.0% | — |
| Net margin | −222.0% | — |
| P/E (TTM) | — | — |
| Price / sales | 21.0× | — |
| Net cash | $601.0M | $250.6M |
| Dividend yield | — | — |
| Volatility (60d) | 64.2% | 48.6% |
| Short % of float | 13.6% | 21.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).